|
1
|
Sapra P and Shor B: Monoclonal
antibody-based therapies in cancer: advances and challenges.
Pharmacol Ther. 138:452–469. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pedersen MW, Jacobsen HJ, Koefoed K, Hey
A, Pyke C, Haurum JS and Kragh M: Sym004: a novel synergistic
anti-epidermal growth factor receptor antibody mixture with
superior anticancer efficacy. Cancer Res. 70:588–597. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sapra P, Damelin M, Dijoseph J, et al:
Long-term tumor regression induced by an antibody-drug conjugate
that targets 5T4, an oncofetal antigen expressed on
tumor-initiating cells. Mol Cancer Ther. 12:38–47. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maron R1, Schechter B, Mancini M,
Mahlknecht G, Yarden Y and Sela M: Inhibition of pancreatic
carcinoma by homo- and heterocombinations of antibodies against
EGF-receptor and its kin HER2/ErbB-2. Proc Natl Acad Sci USA.
110:15389–15394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McCaffery I, Tudor Y, Deng H, et al:
Putative predictive biomarkers of survival in patients with
metastatic pancreatic adenocarcinoma treated with gemcitabine and
ganitumab, an IGF1R inhibitor. Clin Cancer Res. 19:4282–4289. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shankaran V, Obel J and Benson AD III:
Predicting response to EGFR inhibitors in metastatic colorectal
cancer: current practice and future directions. Oncologist.
15:157–167. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Normanno N, De Luca A, Bianco C, et al:
Epidermal growth factor receptor (EGFR) signaling in cancer. Gene.
366:2–16. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hynes NE and Lane HA: ERBB receptors and
cancer: the complexicity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Harrison S and Benziger H: The molecular
biology of colorectal carcinoma and its implications: a review.
Surgeon. 9:200–210. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saxby AJ, Nielsen A, Scarlett CJ, Clarkson
A, Morey A, Gill A and Smith RC: Assessment of HER-2 status in
pancreatic adenocarcinoma: correlation of immunohistochemistry,
quantitative real-time RT-PCR, and FISH with aneuploidy and
survival. Am J Surg Pathol. 29:1125–1134. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yamanaka Y, Friess H, Kobrin MS, Buchler
M, Beger HG and Korc M: Coexpression of epidermal growth factor
receptor and ligands in human pancreatic cancer is associated with
enhanced tumor aggressiveness. Anticancer Res. 13:565–569.
1993.PubMed/NCBI
|
|
12
|
Björklund M and Koivunen E:
Gelatinase-mediated migration and invasion of cancer cells. Biochim
Biophys Acta. 1755:37–69. 2005.PubMed/NCBI
|
|
13
|
Kallakury BV, Karikehalli S, Haholu A,
Sheehan CE, Azumi N and Ross JS: Increased expression of matrix
metalloproteinases 2 and 9 and tissue inhibitors of
metalloproteinases 1 and 2 correlate with poor prognostic variables
in renal cell carcinoma. Clin Cancer Res. 7:3113–3119. 2001.
|
|
14
|
Cho YB, Lee WY, Song SY, Shin HJ, Yun SH
and Chun HK: Matrix metalloproteinase-9 activity is associated with
poor prognosis in T3–T4 node-negative colorectal cancer. Hum
Pathol. 38:1603–1610. 2007.PubMed/NCBI
|
|
15
|
Hong SW, Kang YK, Lee B, et al: Matrix
metalloproteinase-2 and -7 expression in colorectal cancer. J
Korean Soc Coloproctol. 27:133–139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo XF, Zhu XF, Shang Y, Zhang SH and Zhen
YS: A bispecific enediyne-energized fusion protein containing
ligand-based and antibody-based oligopeptides against epidermal
growth factor receptor and human epidermal growth factor receptor 2
shows potent antitumor activity. Clin Cancer Res. 16:2085–2094.
2010. View Article : Google Scholar
|
|
17
|
Zhong G, Zhang S, Li Y, Liu X, Gao R, Miao
Q and Zhen Y: A tandem scFv-based fusion protein and its
enediyne-energized analogue show intensified therapeutic efficacy
against lung carcinoma xenograft in athymic mice. Cancer Lett.
295:124–133. 2010. View Article : Google Scholar
|
|
18
|
Saif MW, Kaley K, Penney R, Hotchkiss S,
Syrigos KN and Strimpakos AS: The efficacy of gemcitabine as
salvage treatment in patients with refractory advanced colorectal
cancer (CRC): a single institution experience. Anticancer Res.
31:2971–2974. 2011.PubMed/NCBI
|
|
19
|
Pelosof L, Yerram SR, Ahujia N, Delmas A,
Danilova L, Herman JG and Azad NS: CHFR silencing or
microsatellite instability is associated with increased antitumor
activity of docetaxel or gemcitabine in colorectal cancer. Int J
Cancer. 134:596–605. 2014. View Article : Google Scholar
|
|
20
|
Shen LC, Chen YK, Lin LM and Shaw SY:
Anti-invasion and anti-tumor growth effect of doxycycline treatment
for human oral squamous-cell carcinoma - in vitro and in vivo
studies. Oral Oncol. 46:178–184. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guimaraes DA, Rizzi E, Ceron CS, et al:
Doxycycline dose-dependently inhibits MMP-2-mediated vascular
changes in 2K1C hypertension. Basic Clin Pharmacol Toxicol.
108:318–325. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Son K, Fujioka S, Iida T, et al:
Doxycycline induces apoptosis in PANC-1 pancreatic cancer cells.
Anticancer Res. 29:3995–4004. 2009.PubMed/NCBI
|
|
23
|
Heinemann V, Douillard JY, Ducreux M and
Peeters M: Targeted therapy in metastatic colorectal cancer - an
example of personalized medicine in action. Cancer Treat Rev.
39:592–601. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Grünwald V and Hidalgo M: Developing
inhibitors of the epidermal growth factor receptor for cancer
treatment. J Natl Cancer Inst. 95:851–867. 2003.PubMed/NCBI
|
|
25
|
Jones S, Zhang X, Parsons DW, et al: Core
signaling pathways in human pancreatic cancers revealed by global
genomic analyses. Science. 321:1801–1806. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Winder T and Lenz HJ: Vascular endothelial
growth factor and epidermal growth factor signaling pathways as
therapeutic targets for colorectal cancer. Gastroenterology.
138:2163–2176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Medinger M and Drevs J: Receptor tyrosine
kinases and anticancer therapy. Curr Pharm Des. 11:1139–1149. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Coussens LM and Werb Z: Matrix
metalloproteinases and the development of cancer. Chem Biol.
3:895–904. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Matsuyama Y, Takao S and Aikou T:
Comparison of matrix metalloproteinase expression between primary
tumors with or without liver metastasis in pancreatic and
colorectal carcinomas. J Surg Oncol. 80:105–110. 2002. View Article : Google Scholar
|
|
30
|
Papadopoulou S, Scorilas A, Arnogianaki N,
Papapanayiotou B, Tzimogiani A, Agnantis N and Talieri M:
Expression of gelatinase-A (MMP-2) in human colon cancer and normal
colon mucosa. Tumour Biol. 22:383–389. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hilska M, Roberts PJ, Collan YU, et al:
Prognostic significance of matrix metalloproteinases-1, -2, -7 and
-13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in
colorectal cancer. Int J Cancer. 121:714–723. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Karakiulakis G, Papanikolaou C, Jankovic
SM, Aletras A, Papakonstantinou E, Vretou E and Mirtsou-Fidani V:
Increased type IV collagen-degrading activity in metastases
originating from primary tumors of the human colon. Invasion
Metastasis. 17:158–168. 1997.PubMed/NCBI
|
|
33
|
Roeb E, Dietrich CG, Winograd R, et al:
Activity and cellular origin of gelatinases in patients with colon
and rectal carcinoma differential activity of matrix
metalloproteinase-9. Cancer. 92:2680–2691. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
35
|
Garden OJ, Rees M, Poston GJ, et al:
Guidelines for resection of colorectal cancer liver metastases.
Gut. 55(Suppl 3): iii1–iii8. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gesto DS1, Cerqueira NM, Fernandes PA and
Ramos MJ: Gemcitabine: a critical nucleoside for cancer therapy.
Curr Med Chem. 19:1076–1087. 2012. View Article : Google Scholar : PubMed/NCBI
|
